Spotlight on Guanglang Biotechnology at 2026 WOF|Bangkok
ASEAN Int'l Optics Expo (WOF | Bangkok) will take place from 9-11 October 2026 in Bangkok, Thailand. Guanglang (Hainan) Biotechnology Co., Ltd. will be present at the expo, showcasing its latest innovations and product highlights.
Company Profile
Guanglang (Hainan) Biotechnology Co., Ltd., established in 2019, is a wholly-owned subsidiary of Guangzhou Shijing Medical Software Co., Ltd. It is a national high-tech enterprise specializing in digital therapy innovation in the ophthalmology field.
Since its establishment, Guanglang has relied on its parent company's over 20 years of accumulation in visual function diagnosis and treatment technology to focus on the research and development of innovative solutions for children's myopia prevention and control. Its own brand "Beibeile" has obtained multiple national Class II medical device registration certificates for various products.
The company has built a research and development system that deeply integrates AI, AR, and VR technologies, and has served over hundreds of thousands of patients. In the future, we will continue to deepen collaborative innovation with top academic institutions, accelerate the construction of the smart medical ecosystem, and provide better digital therapy solutions for the visual health of children and adolescents.
Booth No.5A103
Main Products
1.Duobao VR Visual Function Training System
Duobao VR utilizes its patented technology of binocular separation training method, which achieves binocular disinhibition training through the information content, contrast level, and temporal speed between the left and right eyes. This method improves the vision of amblyopic eyes, promotes binocular coordination, breaks through the bottleneck period of amblyopia treatment, and significantly shortens the treatment period. It also improves the binocular visual function of patients after strabismus surgery, reduces the recurrence rate after surgery, and even eliminates the need for surgery in patients with small-angle strabismus. This provides a better choice for the treatment of strabismus and amblyopia in children.
2.BaBy Blissful PBM-LED myopia treatment device
The BaBy Blissful myopia treatment device emits low-energy, high-brightness, safe red light with a specific wavelength (center wavelength of 645nm±5nm) from the main unit to irradiate the fundus. This significantly improves the blood and oxygen supply to the choroid in the fundus, promotes the growth and thickening of the choroid, thereby inhibiting the growth of the axial length and delaying the progression of myopia.
For more information and pre-registration, please visit www.opticsfair.com.